Drug Type Small molecule drug |
Synonyms LSZ 102 |
Target |
Mechanism ERs antagonists(Estrogen receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H17F3O4S |
InChIKeySJXNPGGVGZXKKI-NYYWCZLTSA-N |
CAS Registry2135600-76-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Estrogen receptor positive breast cancer | Phase 1 | US | 14 Jun 2016 | |
Estrogen receptor positive breast cancer | Phase 1 | JP | 14 Jun 2016 | |
Estrogen receptor positive breast cancer | Phase 1 | BE | 14 Jun 2016 | |
Estrogen receptor positive breast cancer | Phase 1 | FR | 14 Jun 2016 | |
Estrogen receptor positive breast cancer | Phase 1 | DE | 14 Jun 2016 | |
Estrogen receptor positive breast cancer | Phase 1 | IT | 14 Jun 2016 | |
Estrogen receptor positive breast cancer | Phase 1 | SG | 14 Jun 2016 |
Phase 1 | 198 | nojjfdnkev(uupwquobvi) = The most common AEs were gastrointestinal yfjzhoonru (qloirauyfc ) View more | - | 25 Aug 2021 | |||